Psoriatic Arthritis (PsA) Clinical Trial
Official title:
A Trial of Active Psoriatic Arthritis (PsA): Randomizing to Treat to a Target vs. Usual Care
Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.
Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02775656 -
UCB Cimzia Pregnancy Follow-up Study
|
||
| Active, not recruiting |
NCT03671148 -
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
|
Phase 3 | |
| Completed |
NCT03419143 -
Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants
|
||
| Active, not recruiting |
NCT05421442 -
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
|
||
| Recruiting |
NCT04541810 -
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
|